Next-generation therapies for adrenocortical carcinoma.

[1]  D. Hellwig,et al.  Disease Progression after Discontinuation of Nivolumab for Intolerable ImmunotherapyAssociated Polymyalgia Rheumatica in a Patient with Metastasized Adrenocortical Carcinoma: A Case Report and Review of the Literature , 2020 .

[2]  M. Fassnacht,et al.  Expression of SOAT1 in adrenocortical carcinoma and response to mitotane monotherapy: an ENSAT multicenter study. , 2020, The Journal of clinical endocrinology and metabolism.

[3]  M. Fassnacht,et al.  Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma , 2020, Journal for immunotherapy of cancer.

[4]  R. Gentzler,et al.  Epidermal Growth Factor Receptor Mutations. , 2020, Thoracic surgery clinics.

[5]  J. Luke,et al.  Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response , 2020, Clinical Cancer Research.

[6]  A. Rosenwald,et al.  Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma , 2020, Frontiers in Endocrinology.

[7]  G. Tiberio,et al.  Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience , 2020, Cancers.

[8]  G. Arnaldi,et al.  Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma , 2020, Cancers.

[9]  G. Tiberio,et al.  Treatment with 90Y/177Lu DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors. , 2020, The Journal of clinical endocrinology and metabolism.

[10]  M. Fassnacht,et al.  Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study , 2020, Cancers.

[11]  David C. Smith,et al.  A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma , 2020, Investigational new drugs.

[12]  M. Fassnacht,et al.  Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. , 2020, The Journal of clinical endocrinology and metabolism.

[13]  B. Mendonca,et al.  Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma , 2020, Cancers.

[14]  M. Berger,et al.  PD-1 Blockade in Advanced Adrenocortical Carcinoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Abdulkadir,et al.  Nivolumab in metastatic adrenocortical carcinoma: results of a phase II trial. , 2019, The Journal of clinical endocrinology and metabolism.

[16]  G. Arnaldi,et al.  Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment , 2019, Journal of clinical medicine.

[17]  Jeffrey E. Lee,et al.  Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma , 2019, Journal of Immunotherapy for Cancer.

[18]  M. D. De Martino,et al.  The role of mTOR pathway as target for treatment in adrenocortical cancer , 2019, Endocrine connections.

[19]  F. Beuschlein,et al.  Adrenocortical carcinoma — towards genomics guided clinical care , 2019, Nature Reviews Endocrinology.

[20]  P. V. van Koetsveld,et al.  The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures , 2019, The Journal of clinical endocrinology and metabolism.

[21]  M. D. De Martino,et al.  IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer , 2019, Endocrine.

[22]  P. Keegan,et al.  FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors , 2019, Clinical Cancer Research.

[23]  J. Luke,et al.  WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers , 2019, Clinical Cancer Research.

[24]  B. Altieri,et al.  The role of insulin-like growth factor system in the adrenocortical tumors. , 2018, Minerva endocrinologica.

[25]  A. Rosenwald,et al.  Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication , 2018, The Journal of clinical endocrinology and metabolism.

[26]  P. Hoff,et al.  Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden , 2018, Medicine.

[27]  O. Dekkers,et al.  Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis. , 2018, European journal of endocrinology.

[28]  M. Fassnacht,et al.  Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails? , 2018, Experimental and Clinical Endocrinology & Diabetes.

[29]  E. Baudin,et al.  Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. , 2018, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[30]  R. Claus,et al.  Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial , 2018, Journal of Immunotherapy for Cancer.

[31]  M. Cam,et al.  Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors , 2018, Nature Communications.

[32]  M. Juan,et al.  Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Monteiro,et al.  MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors , 2018, Journal of cellular biochemistry.

[34]  C. Austin,et al.  Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response , 2018, Oncotarget.

[35]  I. Mus-Veteau,et al.  Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency , 2018, Cells.

[36]  L. Su,et al.  The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials , 2018, Cancer management and research.

[37]  F. Beuschlein,et al.  Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo , 2018, International journal of cancer.

[38]  S. Movérare-Skrtic,et al.  Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice , 2018, Journal of Endocrinology.

[39]  F. Beuschlein,et al.  Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma , 2018, The Journal of clinical endocrinology and metabolism.

[40]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[41]  Q. Ding,et al.  Nutlin‐3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation , 2018, Cancer medicine.

[42]  Lisa V. Hampson,et al.  A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma , 2018, British Journal of Cancer.

[43]  A. Rosenwald,et al.  ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. , 2018, European journal of endocrinology.

[44]  F. Fauchereau,et al.  A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas , 2017, Aging.

[45]  A. Rosenwald,et al.  Gemcitabine‐Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors , 2017, The Journal of clinical endocrinology and metabolism.

[46]  A. Tolcher,et al.  A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours , 2017, British Journal of Cancer.

[47]  E. Baudin,et al.  Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches , 2017, Oncotarget.

[48]  P. Secchiero,et al.  MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer , 2017, Journal of Hematology & Oncology.

[49]  G. Scagliotti,et al.  Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer. , 2017, Endocrine-related cancer.

[50]  T. Golde,et al.  γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct , 2017, EMBO molecular medicine.

[51]  J. Schellens,et al.  A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. , 2017, European journal of cancer.

[52]  Yi Zhu,et al.  Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma , 2017, Oncotarget.

[53]  S. Loi,et al.  Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). , 2016, The oncologist.

[54]  R. Santi,et al.  Metformin as a new anti-cancer drug in adrenocortical carcinoma , 2016, Oncotarget.

[55]  A. Pontecorvi,et al.  Adrenocortical tumors and insulin resistance: What is the first step? , 2016, International journal of cancer.

[56]  Benjamin J Raphael,et al.  Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. , 2016, Cancer cell.

[57]  T. Kerppola,et al.  ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo. , 2016, Endocrine-related cancer.

[58]  G. Hammer,et al.  ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. , 2016, Endocrinology.

[59]  M. Fassnacht,et al.  Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide , 2016, Hormones and Cancer.

[60]  M. Shen,et al.  Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma , 2016, Clinical Cancer Research.

[61]  R. Carpenter,et al.  Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors , 2016, Cancers.

[62]  K. Bussey,et al.  Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma , 2016, Clinical and Translational Medicine.

[63]  Eleonora Riva,et al.  Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors. , 2015, Biochemical pharmacology.

[64]  M. de Castro,et al.  Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis , 2015, Oncotarget.

[65]  A. Tabarin,et al.  Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  R. Verhaak,et al.  Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. , 2015, Cancer research.

[67]  A. Rosenwald,et al.  Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. , 2015, Endocrinology.

[68]  M. Fassnacht,et al.  Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. , 2015, Endocrine-related cancer.

[69]  A. Gartel,et al.  Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment , 2015, PloS one.

[70]  H. Clevers,et al.  Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia , 2015, Proceedings of the National Academy of Sciences.

[71]  T. Choueiri,et al.  Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. , 2015, The Lancet. Oncology.

[72]  G. Freeman,et al.  Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study , 2015, Journal of Immunotherapy for Cancer.

[73]  M. Papotti,et al.  Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. , 2015, The Journal of clinical endocrinology and metabolism.

[74]  Edward S. Kim,et al.  Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors , 2014, Clinical Cancer Research.

[75]  M. Papotti,et al.  CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma , 2014, PloS one.

[76]  P. Stephens,et al.  Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies , 2014, Journal of Clinical Pathology.

[77]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[78]  Michael Kahn,et al.  Can we safely target the WNT pathway? , 2014, Nature Reviews Drug Discovery.

[79]  G. Hammer,et al.  The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial , 2014, Hormones and Cancer.

[80]  Eric Baudin,et al.  Integrated genomic characterization of adrenocortical carcinoma , 2014, Nature Genetics.

[81]  Helen X. Chen,et al.  Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group , 2014, Pediatric blood & cancer.

[82]  S. Gabriel,et al.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.

[83]  S. Pittaluga,et al.  The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. , 2014, The Journal of clinical endocrinology and metabolism.

[84]  M. Fassnacht,et al.  Update in adrenocortical carcinoma. , 2013, The Journal of clinical endocrinology and metabolism.

[85]  A. Rosenwald,et al.  Single Nucleotide Polymorphism Array Profiling of Adrenocortical Tumors - Evidence for an Adenoma Carcinoma Sequence? , 2013, PloS one.

[86]  Larissa V Furtado,et al.  Adrenocortical carcinoma is a lynch syndrome-associated cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Feng Cong,et al.  Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma , 2013, Proceedings of the National Academy of Sciences.

[88]  R. Verhoeven,et al.  Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. , 2013, European journal of endocrinology.

[89]  R. Kurzrock,et al.  Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer , 2013, Investigational New Drugs.

[90]  G. di Perri,et al.  Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane , 2013, Pharmacogenetics and genomics.

[91]  M. Ro̸rth,et al.  Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study , 2013, British Journal of Cancer.

[92]  A. Buck,et al.  [¹²³I]Iodometomidate imaging in adrenocortical carcinoma. , 2013, The Journal of clinical endocrinology and metabolism.

[93]  E. Baudin,et al.  Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. , 2013, The Journal of clinical endocrinology and metabolism.

[94]  A. Takeshita,et al.  Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. , 2013, The Journal of endocrinology.

[95]  A. Rosato,et al.  Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. , 2012, Endocrine-related cancer.

[96]  M. Fassnacht,et al.  Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. , 2012, The Journal of clinical endocrinology and metabolism.

[97]  C. Schade-Brittinger,et al.  Combination chemotherapy in advanced adrenocortical carcinoma. , 2012, The New England journal of medicine.

[98]  J. García-Donas,et al.  Phase II study of dovitinib in first-line metastatic or nonresectable primary adrenocortical carcinoma (ACC): SOGUG study 2011-03. , 2012 .

[99]  G. Scagliotti,et al.  Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer , 2012, Clinical Cancer Research.

[100]  E. Laufer,et al.  Sonic hedgehog signaling during adrenal development , 2012, Molecular and Cellular Endocrinology.

[101]  T. Giordano,et al.  Upregulated JAG1 Enhances Cell Proliferation in Adrenocortical Carcinoma , 2012, Clinical Cancer Research.

[102]  M. Papotti,et al.  Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. , 2012, European journal of endocrinology.

[103]  A. Buck,et al.  [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[104]  M. Fassnacht,et al.  Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma , 2011, Clinical endocrinology.

[105]  M. Fassnacht,et al.  Sunitinib Inhibits Cell Proliferation and Alters Steroidogenesis by Down-Regulation of HSD3B2 in Adrenocortical Carcinoma Cells , 2011, Front. Endocrin..

[106]  Helen X. Chen,et al.  Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[107]  E. Baudin,et al.  Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. , 2011, The Journal of clinical endocrinology and metabolism.

[108]  B. Ploeger,et al.  Mitotane has a strong and a durable inducing effect on CYP3A4 activity. , 2011, European journal of endocrinology.

[109]  Martin Fassnacht,et al.  Adrenocortical carcinoma: a clinician's update , 2011, Nature Reviews Endocrinology.

[110]  P. Adam,et al.  Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome , 2010, Modern Pathology.

[111]  A. Agha,et al.  Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. , 2010, The Journal of clinical endocrinology and metabolism.

[112]  M. Papotti,et al.  Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. , 2010, Endocrine-related cancer.

[113]  P. Chanson,et al.  Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. , 2010, Endocrine-related cancer.

[114]  G. Hammer,et al.  Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma , 2010, Cancer Chemotherapy and Pharmacology.

[115]  C. Ritter,et al.  Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. , 2010, European journal of endocrinology.

[116]  P. Adam,et al.  Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. , 2009, Endocrine-related cancer.

[117]  N. Mitsiades,et al.  Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. , 2009, Endocrine-related cancer.

[118]  E. Lavezzo,et al.  Investigation of BRAFand CTNNB1 activating mutations in adrenocortical tumors , 2009, Journal of endocrinological investigation.

[119]  F. Beuschlein,et al.  Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma , 2009, Cancer.

[120]  Paul G. Gauger,et al.  Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling , 2009, Clinical Cancer Research.

[121]  D. Bentrem,et al.  Adrenocortical carcinoma in the United States , 2008, Cancer.

[122]  C. Lotfi,et al.  Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. , 2008, The Journal of clinical endocrinology and metabolism.

[123]  F. Beuschlein,et al.  [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. , 2008, The Journal of clinical endocrinology and metabolism.

[124]  P. Adam,et al.  Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. , 2008, The Journal of clinical endocrinology and metabolism.

[125]  W. Oh,et al.  A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC) , 2007 .

[126]  M. Brennan,et al.  An eleven-year experience with adrenocortical carcinoma. , 1992, Surgery.

[127]  Toshimasa J Clark,et al.  Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment. , 2019, The Journal of clinical endocrinology and metabolism.

[128]  Else,et al.  Guidelines on the management of adrenocortical carcinoma in adults , in collaboration with the European Network for the Study of Adrenal Tumors , 2018 .

[129]  M. Memo,et al.  Palbociclib inhibits proliferation of human adrenocortical tumor cells , 2017, Endocrine.

[130]  Yuhree Kim,et al.  Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence , 2015, Annals of Surgical Oncology.

[131]  S. Jolly,et al.  Adrenocortical Carcinoma , 2010, Cancers.

[132]  F. Janku,et al.  Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer , 2013, Investigational New Drugs.

[133]  R. Kuick,et al.  Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.